Site comparison
Amavita Research vs. Academic Medical Center Sites
How an independent investigator-led site differs from a typical academic medical center cardiovascular trial site — by criteria sponsors care about.
Sponsors evaluating cardiovascular trial sites in the U.S. typically choose between two structural archetypes: academic medical centers (AMCs) with cardiology fellowship programs and CTSA-funded research infrastructure, and independent investigator-led sites operating inside private cardiology practices. Both can run high-quality trials. The differences that matter to sponsor decision-making are speed-to-first-patient, patient-flow predictability, PI decision authority, cost structure, and trial-cohort competition. Here's how Amavita Research compares to a typical AMC site on each.
Side-by-side: decision criteria
Educational summary. We describe the typical academic medical center model and do not make claims about any specific institution's current operations.
| Criterion | Amavita Research | Typical AMC site |
|---|---|---|
| Site type | Independent investigator-led, inside amavita Heart and Vascular Health® | Academic medical center with cardiology fellowship program |
| Contract-to-first-patient | 5–8 weeks for trial types already qualified | 10–16 weeks typical (AMC contracting + IRB cycle) |
| Patient flow | Trial-eligible patients walk into amavita Heart and Vascular Health® clinics for routine cardiology care every business day; screened in real time by the same physicians who serve as Principal Investigators | Patient flow depends on internal referrals across multiple departments and on the AMC's clinical-trial liaison process |
| PI decision authority | Single PI on each protocol; decisions in days | Decisions often require multi-stakeholder sign-off (PI, department chair, research office) |
| Cath-lab access | Direct access to amavita Heart and Vascular Health® cath-lab and the affiliated Advanced Cardiovascular of Miami ambulatory surgical center | Cath-lab time shared with surgical training programs and competing service lines |
| Cost structure | 20–30% lower than high-end private-equity-backed Miami site networks; no academic overhead, no MSO carve-out | Higher overhead from indirect costs (typically 25–35% F&A), institutional research office fees, fellowship-program subsidies |
| Trial-cohort competition | No competing trials within the same indication unless sponsor approves co-enrollment | AMCs commonly have multiple competing trials within the same indication; patient eligibility splits across studies |
| Quality framework | IAOCR GCSA recertified May 2026 (valid through Feb 2027), ICH-GCP E6(R3) compliant, SCRS member, Zero FDA inspection findings to date | AMCs vary; large AMCs typically run their own quality programs but inspection histories are variable |
| Hybrid US + Latin America designs | Available via tight integration with sister organization bioaccess® (Latin America first-in-human CRO) | Most AMCs don't offer integrated cross-border designs |
When to choose Amavita Research
- You want speed-to-first-patient and a single PI decision-maker
- You're running a feasibility, first-in-human, or pivotal cardiovascular trial where named PI quality matters
- You want predictable patient flow from a continuously-recruiting cardiology practice
- You're cost-sensitive and want to avoid academic overhead
- You want a Latin America arm under the same protocol via bioaccess® integration
When an AMC site may fit better
- Your protocol requires sub-specialties Amavita doesn't currently cover (e.g., advanced heart failure transplant, congenital cardiology, certain cardiac surgical interventions)
- You need access to a CTSA-funded biorepository or specific imaging core lab housed inside an AMC
- Your sponsor program requires AMC affiliation for grant reasons or for academic publication leverage
- You're running a registry that benefits from AMC patient diversity at scale
Decision-criteria summary
For most cardiovascular feasibility, pivotal, and first-in-human trials in 2026, the speed, cost, and patient-flow advantages of an independent investigator-led site outweigh the institutional advantages of an AMC — assuming the indication fits the site's qualification scope. Sponsors who choose Amavita Research are typically optimizing for predictable enrollment timelines, named-PI accountability, and capital efficiency.
Next step
Talk to Amavita Research about your protocol
One PI. One BD contact. Same-business-day response on feasibility, budget, and contracts.
For a comprehensive sponsor decision framework, read our 2026 site selection guide.